EverSource Wealth Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

EverSource Wealth Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.3K	Buy	12,614 +9,668	+328%	+$32.2K	﹤0.01%	1826
2026 Q1	$9.04K	Buy	2,946 +141	+5%	+$545	﹤0.01%	2964
2025 Q4	$11.5K	Sell	2,805 -6,100	-69%	-$30.2K	﹤0.01%	2727
2025 Q3	$43.5K	Buy	8,905 +1,625	+22%	+$8.53K	﹤0.01%	1799
2025 Q2	$36.8K	Sell	7,280 -101,349	-93%	-$498K	﹤0.01%	1825
2025 Q1	$575K	Buy	108,629 +108,514	+94,360%	+$791K	0.03%	352
2024 Q4	$777	Buy	+115	New	+$773	﹤0.01%	3052
2024 Q3	–	Sell	-64	Closed	-$525	–	3109
2024 Q2	$525	Buy	+64	New	+$558	﹤0.01%	2879

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

EverSource Wealth Advisors's RXRX Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 328% in Q2 2026, buying an estimated $32.2K and bringing the position to 12,614 shares worth $46.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1826.

EverSource Wealth Advisors first reported a position in RXRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $575K in Q1 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

EverSource Wealth Advisors held 12,614 shares of Recursion Pharmaceuticals worth $46.3K as of Q2 2026.
EverSource Wealth Advisors bought 9,668 Recursion Pharmaceuticals shares in Q2 2026, an estimated $32.2K.
Recursion Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #1826 holding.
EverSource Wealth Advisors first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
EverSource Wealth Advisors's Recursion Pharmaceuticals position peaked at $575K in Q1 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.